USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION

Abstract
The present invention is a method for the treatment of substance abuse and/or addiction comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-heteroaryl sulfamide derivatives of formula (I) as herein defined.
Description
Claims
  • 1. A method of treating substance abuse or addiction comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula (I)
  • 2. The method of claim 1 wherein R1 is selected from the group consisting of hydrogen, halogen, trifluoromethyl, cyano and nitro;X—Y is selected from the group consisting of —S—CH—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;A is selected from the group consisting of —CH2— and —CH(CH3)—;R2 is selected from the group consisting of hydrogen and methyl;R3 and R4 are each independently selected from the group consisting of hydrogen, methyl and ethyl;or a pharmaceutically acceptable salt thereof.
  • 3. The method of claim 2, wherein R1 is selected from the group consisting of hydrogen, halogen, trifluoromethyl and cyano;X—Y is selected from the group consisting of —S—CH—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;A is selected from the group consisting of —CH2— and —CH(CH3)—;R2 is hydrogen;R3 and R4 are each independently selected from the group consisting of hydrogen and ethyl;or a pharmaceutically acceptable salt thereof.
  • 4. The method of claim 3, wherein R1 is selected from the group consisting of hydrogen, 5-chloro, 5-fluoro, 5-bromo, 4-bromo, 7-fluoro, 5-trifluoromethyl and 5-cyano;X—Y is selected from the group consisting of —S—CH—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;A is selected from the group consisting of —CH2— and —CH(CH3)—;R2 is hydrogen;R3 and R4 are each hydrogen; alternatively R3 is hydrogen and R4 is ethyl;or a pharmaceutically acceptable salt thereof.
  • 5. The method of claim 1, wherein R1 is selected from the group consisting of hydrogen, halogen, trifluoromethyl and cyano;X—Y is selected from the group consisting of —S—CH—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;A is selected from the group consisting of —CH2— and —CH(CH3)—;R2 is selected from the group consisting of hydrogen and methyl;R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 to 7 membered, saturated, partially unsaturated or aromatic ring structure, optionally containing one to two additional heteroatoms independently selected from the group consisting of O, N and S;or a pharmaceutically acceptable salt thereof.
  • 6. The method of claim 5, wherein R1 is selected from the group consisting of hydrogen, halogen, trifluoromethyl and cyano;X—Y is selected from the group consisting of —S—CH—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;A is selected from the group consisting of —CH2— and —CH(CH3)—;R2 is selected from the group consisting of hydrogen and methyl;R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 to 6 membered, saturated or aromatic ring structure, optionally containing one to two additional heteroatoms independently selected from the group consisting of O, N and S;or a pharmaceutically acceptable salt thereof.
  • 7. The method of claim 6, wherein R1 is hydrogen;X—Y is —S—CH—;A is —CH2—;R2 is hydrogen;R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 membered ring structure selected from the group consisting of pyrrolidinyl and imidazolyl;or a pharmaceutically acceptable salt thereof.
  • 8. The method of claim 2, wherein the compound of formula (I) is selected from the group consisting of N-(benzo[b]thien-3-yl methyl )-sulfamide;N-[(5-chlorobenzo[b]thien-3-yl)methyl]-sulfamide;N-(3-benzofuranylmethyl)-sulfamide;N-[(5-fluorobenzo[b]thien-3-yl)methyl]-sulfamide;N-(1-benzo[b]thien-3-ylethyl)-sulfamide;N-(1-naphthalenylmethyl)-sulfamide;N-[(2-methyl-3-benzofuranyl)methyl]-sulfamide;N-[(5-bromobenzo[b]thien-3-yl)methyl]-sulfamide;N-[(4-bromobenzo[b]thien-3-yl)methyl]-sulfamide;N-[(7-fluorobenzo[b]thien-3-yl)methyl]-sulfamide;N-[(1-methyl-1H-indol-3-yl)methyl]-sulfamide;N-[(4-trifluoromethylbenzo[b]thien-3-yl)methyl]-sulfamide;N-[(4-cyanobenzo[b]thien-3-yl)methyl]-sulfamide;N-[(benzo[b]thien-3-yl)methyl]-sulfamoylpyrrolidine;N-[(benzo[b]thien-3-yl)methyl]-N′-ethylsulfamide;imidazole-1-sulfonic acid [(benzo[b]thien-3-yl)methyl]-amide;and pharmaceutically acceptable salts thereof.
  • 9. The method of claim 1, wherein the compound of formula (I) is selected from the group consisting of N-(benzo[b]thien-3-ylmethyl)-sulfamide; N-[(5-fluorobenzo[b]thien-3-yl)methyl]-sulfamide; and pharmaceutically acceptable salts thereof.
  • 10. A method of treating substance abuse or addiction comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of N-(benzo[b]thien-3-ylmethyl)-sulfamide and pharmaceutically acceptable salts thereof.
  • 11. The method of claim 1 wherein the substance of abuse or addiction is selected from the group consisting of alcohol, cocaine, heroine, methamphetamine, ketamine, Ecstacy, nicotine, oxycontin/oxycodone, codeine and morphine.
  • 12. The method of claim 1, wherein the substance of abuse or addiction is selected from the group consisting of alcohol, cocaine, heroine, methamphetamine and nicotine.
  • 13. The method of claim 1, wherein the substance of abuse or addiction is alcohol or nicotine.
  • 14. The method of claim 1, wherein the substance of abuse or addiction is alcohol.
  • 15. The method of claim 10, wherein the substance of abuse or addiction is selected from the group consisting of alcohol, cocaine, heroine, methamphetamine, ketamine, Ecstacy, nicotine, oxycontin/oxycodone, codeine and morphine.
  • 16. The method of claim 10, wherein the substance of abuse or addiction is selected from the group consisting of alcohol, cocaine, heroine, methamphetamine and nicotine.
  • 17. The method of claim 10, wherein the substance of abuse or addiction is alcohol or nicotine.
  • 18. The method of claim 10, wherein the substance of abuse or addiction is alcohol.
Provisional Applications (1)
Number Date Country
60773724 Feb 2006 US